Is it Finally Time to Buy Medical Properties Trust?
Medical Properties Trust (NYSE:MPW) is a REIT that focuses on…
Sell
34
FBRX Quote, Financials, Valuation and Earnings
Last price:
$7.64
Seasonality move
:
-14.46%
Day range:
$7.10 - $8.21
52-week range:
$4.11 - $28.68
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.23x
Volume:
66K
Avg. volume:
43.2K
1-year change:
-52.89%
Market cap:
$11.6M
Revenue:
--
EPS (TTM):
-$16.32
Analysts' Opinion
-
Consensus RatingForte Biosciences has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Forte Biosciences has an estimated upside of 1252.72% from its current price of $8.20.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $8.20.
Fair Value
-
According to the consensus of 3 analysts, Forte Biosciences has 1252.72% upside to fair value with a price target of -- per share.
FBRX vs. S&P 500
-
Over the past 5 trading days, Forte Biosciences has overperformed the S&P 500 by 4.43% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Forte Biosciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Forte Biosciences has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Forte Biosciences reported revenues of --.
Earnings Growth
-
Forte Biosciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Forte Biosciences reported earnings per share of -$4.54.
Enterprise value:
-4.8M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.16x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$12.3M | -$31M | -$35.6M | -$10.2M | -$8.6M | |
| EBITDA | -$12.3M | -$31M | -$35.6M | -$10.2M | -$8.6M | |
| Diluted EPS | -$19.25 | -$31.07 | -$16.32 | -$6.57 | -$4.54 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $21.6M | $46.6M | $44.6M | $47.1M | $17.7M | |
| Total Assets | $22.7M | $47.4M | $45.1M | $47.9M | $17.9M | |
| Current Liabilities | $2.4M | $3.7M | $2.3M | $7.5M | $8.6M | |
| Total Liabilities | $2.4M | $3.7M | $2.3M | $7.5M | $8.6M | |
| Total Equity | $20.3M | $43.7M | $42.8M | $40.4M | $9.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$8.9M | -$22.6M | -$29.7M | -$9.1M | -$8.1M | |
| Cash From Investing | -- | $63K | -$22K | $10M | -- | |
| Cash From Financing | $7.3M | $24.7M | -$95K | $24.8M | -$2K | |
| Free Cash Flow | -$8.9M | -$22.6M | -$29.7M | -$9.1M | -$8.1M | |
FBRX
Sector
Market Cap
$11.6M
$36.5M
Price % of 52-Week High
27.58%
44.66%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.9%
1-Year Price Total Return
-54.47%
-39.9%
Beta (5-Year)
2.352
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$7.73
200-day SMA
Sell
Level
$11.51
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$7.02
Relative Strength Index (RSI14)
Sell
Level
49.58
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-35.4115
50-day SMA
Sell
Level
$10.76
MACD (12, 26)
Sell
Level
-0.79
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
--
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).
Stock Forecast FAQ
In the current month, FBRX has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The FBRX average analyst price target in the past 3 months is --.
-
Where Will Forte Biosciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Forte Biosciences share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Forte Biosciences?
Analysts are divided on their view about Forte Biosciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Forte Biosciences is a Sell and believe this share price will drop from its current level to --.
-
What Is Forte Biosciences's Price Target?
The price target for Forte Biosciences over the next 1-year time period is forecast to be -- according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is FBRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Forte Biosciences is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of FBRX?
You can purchase shares of Forte Biosciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Forte Biosciences shares.
-
What Is The Forte Biosciences Share Price Today?
Forte Biosciences was last trading at $7.64 per share. This represents the most recent stock quote for Forte Biosciences. Yesterday, Forte Biosciences closed at $8.20 per share.
-
How To Buy Forte Biosciences Stock Online?
In order to purchase Forte Biosciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Signet Jewelers Stock Go Up So Much?
Signet Jewelers (NYSE:SIG) is the largest diamond retailer in the…
Why Did HealthEquity Stock Fall So Much?
HealthEquity (NASDAQ:HQY) is a fintech company that acts as an…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
44
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
54
CNXC alert for Mar 29
Concentrix [CNXC] is down 12.39% over the past day.
Buy
74
SLNO alert for Mar 28
Soleno Therapeutics [SLNO] is up 6.8% over the past day.
Sell
44
CAR alert for Mar 29
Avis Budget Group [CAR] is up 0.71% over the past day.
